Michael J. Yee

Axovant Sciences Ltd (NASDAQ: AXON) plummeted 25 percent last week, providing an attractive entry point, as the company is in-licensing two promising orphan gene therapy programs that could have data coming over the next three to 12 months, according to Jefferies. The Analyst Jefferies' analyst...

Biotechnology stocks got killed on Monday, after Democratic presidential candidate Hillary Clinton tweeted, “Price gouging like this in the specialty drug market is outrageous. Tomorrow I'll lay out a plan to take it on.” The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:...

Encouraging early results from a trial of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) dwarfism treatment sent the company's shares higher Thursday while analysts boosted their targets. Shares changed hands recently at $138.50, up 12 percent. BioMarin said a trial of its vosoritide drug in...